Halberd and GTX Corp. Sign Scientific Collaboration and Reseller Agreement - Seite 2
To get the latest news on Halberd's exciting medical developments, including our ongoing disease eradication accomplishments, subscribe by submitting this form.
(https://halberdcorporation.com/contact-us/)
For more information please contact:
William A. Hartman
w.hartman@halberdcorporation.com;
support@halberdcorporation.com
http://www.halberdcorporation.com
Twitter:@HalberdC
About GTX Corp.
GTX Corp (OTC PINK:GTXO) is a pioneer in smart, mobile and wearable GPS tracking and recovery location-based solutions, supported through a proprietary IoT enterprise monitoring platform and
intellectual property portfolio. GTX offers a global end-to-end solution of hardware, software and connectivity and develops two-way GPS tracking technologies, which seamlessly integrate with
consumer products and enterprise applications. GTX utilizes the latest in miniaturized, low power consumption GPS, Cellular, RF, NFC and BLE technology, enabling subscribers to track in real time
the whereabouts of people or high value assets. GTX is known for its game-changing and award-winning patented GPS
SmartSole® -- the world's first invisible wearable technology tracking device created for those at risk of wandering due to Alzheimer's, dementia, autism and traumatic brain injury.
GTX's business model is built around technology innovation and holds over 85 patents, with many issued patents in the area of GPS tracking. The company has international distributors servicing
customers in over 35 countries and is a U.S. Military Government contractor. Other customers include public health authorities and municipalities, emergency and law enforcement, private schools,
assisted living facilities, NGOs, small business enterprises, senior care homes, and consumers.
GTXCorp.com
Track My Workforce
GPS SmartSole.com
Lesen Sie auch
About Halberd Corporation.
Halberd Corporation (OTC PINK:HALB), is a publicly traded company on the OTC Market, and is in full compliance with OTC
Market reporting requirements. It holds the exclusive worldwide rights to several patent- and PCT-pending extracorporeal treatments for COVID-19 and other medical maladies: Halberd also holds the
exclusive rights to the underlying granted U.S. Patent 9,216,386 and U.S. Patent 8,758,287 and an allowed but not yet issued patent for the treatment of Cockayne Syndrome